Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > AmStem Appoints Dr. Thomas W. Prendergast to Scientific and Medical Board of Advisors

Abstract:
Cardiothoracic Surgeon Specializes in Heart Transplantation and Repair

AmStem Appoints Dr. Thomas W. Prendergast to Scientific and Medical Board of Advisors

San Francisco, CA & Seoul, Korea | Posted on September 14th, 2010

AmStem Corporation (OTCBB: AMSTE), a leading provider of biotherapeutic and cosmetic stem cell products, stem cell collection and storage expertise and access to nanotechnology vital to stem cell research, announced today the addition of heart transplantation and repair physician Dr. Thomas W. Prendergast, M.D. as Vice-Chairman of its Scientific and Medical Board of Advisors (SAMBA).

AmStem President Dwight Brunoehler said, "We are assembling a top tier group of clinical and laboratory experts for our Scientific and Medical Board of Advisors. Tom Prendergast is a tremendous addition. As Vice-Chairman, he will be assisting Drs. Han and Lowry in guiding the company's research and intellectual property development. He is a busy clinical cardiothoracic surgeon performing 200-250 open-heart operations and 5-15 heart transplants a year. He is deeply involved in numerous clinical and research activities associated with stem cells and heart repair.

"AmStem is most fortunate to have Dr. Prendergast take a leadership role on our advisory board. His expertise in the use of stem cells for myocardial repair in heart patients is leading the way for stem cell use in regenerative medicine. In addition, Dr. Prendergast will be an invaluable member of our SAMBA team by assisting AmStem in forging research and economic development opportunities between Korea and the United States," Brunoehler said.

Dr. Prendergast said, "I am looking forward with excitement to the opportunities I see at AmStem. Dwight is an accomplished leader and I am anxious to start work supporting and forwarding the pioneering stem cell work of Dr. Han and his Korean team who have the vision to move the company and its stem cell assets into the exciting future of regenerative medicine."

Dr. Prendergast is presently director of Cardiac Transplantation at Robert Wood Johnson University Hospital in New Brunswick, New Jersey where he holds an Associate Professorship of Surgery at the University of Medicine and Dentistry of New Jersey. In addition to being an active participant in stem cell research program development and teaching medical students and residents, his other interests include medical research funding and humanitarian development of programs for Disabled American Veterans.

Dr. Prendergast received his undergraduate degrees in Biophysics and Psychology, as well as his medical degree, at Pennsylvania State University. His General Surgery residency was for five years at the University of Massachusetts Medical School. Cardiothoracic Surgery training was at the University of Southern California School of Medicine, including the Los Angeles County Medical Center. Subsequent fellowship training included Pediatric Cardiac Surgery at Children's Hospital of LA, along with Thoracic Transplant fellowships at University of Southern California in LA and at Temple University Hospital in Philadelphia. He spent three years at the University of Kansas establishing thoracic transplant programs until returning to Temple University Hospital as one of the staff heart and lung transplant surgeons. Subsequent to his time at Temple, he joined up with Newark Beth Israel/St. Barnabas Hospitals, where he assumed directorship as the Chief of Cardiac Transplantation and Mechanical Assistance.

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for AmStem Corporation may be forward-looking statements that involve a number of risks and uncertainties. For these statements, we claim the protection of the safe harbor for forward-looking statement contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, successfully complete clinical trials, our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capability or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in the press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statement to reflect events or circumstances that occur after the date hereof.

####

About AmStem Corporation
AmStem Inc. is a corporation registered in the State of Nevada with offices in San Francisco, California and Seoul, Korea. The company is a world leader in the area of stem cell research using stem cells derived from the umbilical cord immediately after birth. The company has 19 U.S. and international patents related to stem cell processing, application and clinical treatments. AmStem owns one of the largest cord blood stem cell banks in the world with more than 80,000 cord blood units stored in Korea. The facility in Korea is highly accredited including Korean FDA approval (KFDA). The units of cord blood are processed and stored by the company for use in unrelated transplant for personal storage and use in the family setting for transplant and regenerative medicine. The company is developing a line of cosmeceuticals based upon its proprietary stem cell technology and sourcing its own materials from its expansive operation in Korea. The company has treated more than 800 people in clinical trials for purposes of developing its patent portfolio.

For more information contact AmStem President Dwight Brunoehler at (415) 956-2410 or Tom Fox at Hawk Associates at (305) 451-1888 or visit: amsteminc.com.

For more information, please click here

Contacts:
AmStem Corporation
Dwight Brunoehler, 415-956-2410
or
Hawk Associates
Tom Fox, 305-451-1888

Copyright © AmStem Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Three-dimensional graphene: Experiment at BESSY II shows that optical properties are tuneable May 24th, 2017

Leti to Demo 1st Wireless UNB Transceiver for ‘Massive Internet of Things’ at RFIC 2017 and IMS 2017: Leti Will also Present Three Papers & Two Workshops on 5G Communications IC Design, from RF to mm-Wave, During IMS 2017 and RFIC 2017 in Hawaii May 24th, 2017

GLOBALFOUNDRIES and Chengdu Partner to Expand FD-SOI Ecosystem in China: More than $100M investment to establish a center of excellence for FDXTM FD-SOI design May 23rd, 2017

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Announcements

Three-dimensional graphene: Experiment at BESSY II shows that optical properties are tuneable May 24th, 2017

Leti to Demo 1st Wireless UNB Transceiver for ‘Massive Internet of Things’ at RFIC 2017 and IMS 2017: Leti Will also Present Three Papers & Two Workshops on 5G Communications IC Design, from RF to mm-Wave, During IMS 2017 and RFIC 2017 in Hawaii May 24th, 2017

GLOBALFOUNDRIES and Chengdu Partner to Expand FD-SOI Ecosystem in China: More than $100M investment to establish a center of excellence for FDXTM FD-SOI design May 23rd, 2017

Zap! Graphene is bad news for bacteria: Rice, Ben-Gurion universities show laser-induced graphene kills bacteria, resists biofouling May 22nd, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer: Oncology industry veteran to oversee operations and product commercialization February 8th, 2017

Dr Barbara Armbruster promoted to Worldwide Sales and Marketing Director for XEI Scientific September 27th, 2016

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project